Osteocalcin promoter directed adenovirus replicaton for therapy
CA 2403795 A1 · Owner: The University Of Virginia Patent Foundation · Inventors: Gardner, Thomas A.; Chung, Leland W. K.; Ko, Song-Chu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to replication-competent adenovirus vectors which are specific for cells which allow an osteocalcin transcriptional regulatory sequence to function, such as prostate cancer cells prostate , stromal cells, vascular pericytes proliferating cancer-associated , osteoblasts and prostate cancer and associated bone stromal cells which fail to express PSA or androgen receptor (AR) and methods of use of such viruses , are provided. These viruses comprise an adenoviral gene under control of an osteocalcin transcriptional regulatory sequence. The gene can be for example, a gene required for adenoviral replication. The viruses can also comprise at least one additional …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 21, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 21, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 21, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.